CY1118644T1 - Ενωση καρβοξαμιδιου πυραζινης - Google Patents

Ενωση καρβοξαμιδιου πυραζινης

Info

Publication number
CY1118644T1
CY1118644T1 CY20171100230T CY171100230T CY1118644T1 CY 1118644 T1 CY1118644 T1 CY 1118644T1 CY 20171100230 T CY20171100230 T CY 20171100230T CY 171100230 T CY171100230 T CY 171100230T CY 1118644 T1 CY1118644 T1 CY 1118644T1
Authority
CY
Cyprus
Prior art keywords
egfr
mutation
positive
another embodiment
lung cancer
Prior art date
Application number
CY20171100230T
Other languages
English (en)
Inventor
Takahiro Matsuya
Yutaka Kondoh
Itsuro Shimada
Shigetoshi Kikuchi
Maiko Iida
Kenichi Onda
Hiroki Fukudome
Yukihiro Takemoto
Nobuaki Shindou
Hideki Sakagami
Hisao Hamaguchi
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48799179&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118644(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1118644T1 publication Critical patent/CY1118644T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

[Πρόβλημα] Μια ένωση η οποία είναι χρήσιμη ως ένας αναστολέας στη δραστηριότητα της κινάσης μετάλλαξης Τ790Μ του EGFR παρέχεται. [Μέσα για Επίλυση] Οι παρόντες εφευρέτες έχουν ερευνήσει μια ένωση έχοντας μια ανασταλτική δράση σε μια κινάση μετάλλαξης Τ790Μ του EGFR, και έχουν βρει ότι μια ένωση πυραζινκαρβοξαμιδίου έχει μια ανασταλτική δράση σε μια κινάση μετάλλαξης Τ790Μ του EGFR, συμπληρώνοντας ως εκ τούτου την παρούσα εφεύρεση. Η ένωση πυραζινκαρβοξαμιδίου της παρούσας εφεύρεσης έχει μια ανασταλτική δράση σε μια κινάση μετάλλαξης Τ790Μ του EGFR, και μπορεί να χρησιμοποιηθεί ως ένας παράγων για πρόληψη και/ή αγωγή του θετικού σε μετάλλαξη Τ790Μ του EGFR καρκίνου, σε μια άλλη ενσωμάτωση, του θετικού σε μετάλλαξη Τ790Μ του EGFR καρκίνου του πνευμόνων, σε μια ακόμη άλλη ενσωμάτωση, του θετικού σε μετάλλαξη Τ790Μ του EGFR μη-μικροκυτταρικού καρκίνου των πνευμόνων, σε ακόμη περαιτέρω μια άλλη ενσωμάτωση, του θετικού σε πρωτεΐνη μετάλλαξης Τ790Μ του EGFR καρκίνου, σε ακόμη περαιτέρω μια άλλη ενσωμάτωση, του θετικού σε πρωτεΐνη μετάλλαξης Τ790Μ του EGFR καρκίνου των πνευμόνων, σε ακόμη περαιτέρω μια άλλη ενσωμάτωση, του ανθεκτικού σε αναστολέα κινάσης τυροσίνης του EGFR καρκίνου, σε μια ακόμη περαιτέρω άλλη ενσωμάτωση, του ανθεκτικού σε αναστολέα κινάσης τυροσίνης του EGFR καρκίνου των πνευμόνων, και σε ακόμη περαιτέρω μια άλλη ενσωμάτωση, του ανθεκτικού σε αναστολέα κινάσης τυροσίνης του EGFR μη-μικροκυτταρικού καρκίνου των πνευμόνων, ή των παρόμοιων.
CY20171100230T 2012-01-17 2017-02-20 Ενωση καρβοξαμιδιου πυραζινης CY1118644T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012007525 2012-01-17
PCT/JP2013/050579 WO2013108754A1 (ja) 2012-01-17 2013-01-15 ピラジンカルボキサミド化合物

Publications (1)

Publication Number Publication Date
CY1118644T1 true CY1118644T1 (el) 2017-07-12

Family

ID=48799179

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100230T CY1118644T1 (el) 2012-01-17 2017-02-20 Ενωση καρβοξαμιδιου πυραζινης

Country Status (30)

Country Link
US (1) US9085540B2 (el)
EP (1) EP2805940B1 (el)
JP (1) JP5532366B2 (el)
KR (1) KR101985050B1 (el)
CN (1) CN104080774B (el)
AR (1) AR089727A1 (el)
AU (1) AU2013210438B2 (el)
BR (1) BR112014017466A8 (el)
CA (1) CA2860765C (el)
CY (1) CY1118644T1 (el)
DK (1) DK2805940T3 (el)
EA (1) EA026353B1 (el)
ES (1) ES2613399T3 (el)
HK (1) HK1203491A1 (el)
HR (1) HRP20170226T1 (el)
HU (1) HUE033177T2 (el)
IL (1) IL233437A (el)
LT (1) LT2805940T (el)
ME (1) ME02648B (el)
MX (1) MX355434B (el)
PH (1) PH12014501456A1 (el)
PL (1) PL2805940T3 (el)
PT (1) PT2805940T (el)
RS (1) RS55704B1 (el)
SI (1) SI2805940T1 (el)
SM (1) SMT201700094B (el)
TW (1) TWI532727B (el)
UA (1) UA111010C2 (el)
WO (1) WO2013108754A1 (el)
ZA (1) ZA201405045B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2982666B1 (en) * 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
DK3060550T3 (da) * 2013-10-21 2019-07-22 Merck Patent Gmbh Heteroarylforbindelser som btk-inhibitorer og anvendelser deraf
EP3077384B1 (en) * 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
MX2016007111A (es) * 2013-12-05 2016-08-11 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CN106456636A (zh) * 2014-05-28 2017-02-22 安斯泰来制药株式会社 包含吡嗪甲酰胺化合物作为活性成分的药物组合物
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
KR20170105021A (ko) * 2015-01-28 2017-09-18 아스테라스 세이야쿠 가부시키가이샤 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
EP3290036A4 (en) * 2015-04-27 2019-01-02 Astellas Pharma Inc. Stabilized pharmaceutical composition
JP2018104290A (ja) * 2015-04-28 2018-07-05 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
CN107709315A (zh) * 2015-06-02 2018-02-16 药品循环有限责任公司 布鲁顿酪氨酸激酶的抑制剂
EP3310771B1 (en) * 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
JP2019014653A (ja) * 2015-11-27 2019-01-31 アステラス製薬株式会社 がん免疫を介したがん治療方法
CA3228632A1 (en) * 2015-12-24 2017-06-29 Kyowa Kirin Co., Ltd. .alpha.,.beta.-unsaturated amide compound
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
US20190282569A1 (en) * 2016-10-26 2019-09-19 Astellas Pharma Inc. Stable pharmaceutical composition
WO2018103663A1 (zh) * 2016-12-09 2018-06-14 深圳市塔吉瑞生物医药有限公司 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
KR20200019979A (ko) * 2017-06-23 2020-02-25 쿄와 기린 가부시키가이샤 α, β 불포화 아미드 화합물
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
US11691974B2 (en) 2018-09-30 2023-07-04 Medshine Discovery Inc. 3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors
CN112062728A (zh) * 2019-05-25 2020-12-11 上海鑫凯化学科技有限公司 一种3,5-二氯-6-乙基吡嗪甲酰胺的合成方法
JP2023501989A (ja) * 2019-11-13 2023-01-20 ジェネンテック， インコーポレイテッド 治療用化合物および使用方法
CN111266090B (zh) * 2020-02-19 2022-11-15 渤海大学 一种快速吸附和选择性分离阳离子染料污染物的吸附分离材料及其应用
US20230167099A1 (en) * 2020-06-01 2023-06-01 Wigen Biomedicine Technology (shanghai) Co., Ltd. New pyrazine compound
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
EP4308559A1 (en) 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
BR0318503A (pt) 2003-09-15 2006-09-12 Wyeth Corp quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
DK1746999T3 (da) 2004-05-06 2012-01-23 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amider
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
TWI475996B (zh) 2007-10-19 2015-03-11 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009136995A2 (en) * 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
JP5705720B2 (ja) * 2008-04-16 2015-04-22 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
WO2010129053A2 (en) * 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
ES2667706T3 (es) * 2009-05-08 2018-05-14 Astellas Pharma Inc. Compuesto de diamino-carboxamida heterocíclica
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith

Also Published As

Publication number Publication date
TW201341373A (zh) 2013-10-16
KR101985050B1 (ko) 2019-05-31
ME02648B (me) 2017-06-20
HK1203491A1 (en) 2015-10-30
US9085540B2 (en) 2015-07-21
ES2613399T3 (es) 2017-05-24
JPWO2013108754A1 (ja) 2015-05-11
LT2805940T (lt) 2017-01-10
EP2805940A4 (en) 2015-04-15
UA111010C2 (uk) 2016-03-10
TWI532727B (zh) 2016-05-11
EA201491371A1 (ru) 2014-11-28
CA2860765C (en) 2018-06-26
CN104080774B (zh) 2017-02-22
CA2860765A1 (en) 2013-07-25
US20140323463A1 (en) 2014-10-30
DK2805940T3 (en) 2017-02-06
RS55704B1 (sr) 2017-07-31
JP5532366B2 (ja) 2014-06-25
WO2013108754A1 (ja) 2013-07-25
PL2805940T3 (pl) 2017-06-30
ZA201405045B (en) 2016-01-27
KR20140114404A (ko) 2014-09-26
MX355434B (es) 2018-04-18
AU2013210438A1 (en) 2014-07-17
SMT201700094B (it) 2017-03-08
IL233437A (en) 2017-01-31
EP2805940B1 (en) 2016-11-23
IL233437A0 (en) 2014-08-31
EP2805940A1 (en) 2014-11-26
CN104080774A (zh) 2014-10-01
BR112014017466A2 (pt) 2017-06-13
HUE033177T2 (en) 2017-11-28
AR089727A1 (es) 2014-09-10
BR112014017466A8 (pt) 2017-07-04
PH12014501456A1 (en) 2014-10-08
HRP20170226T1 (hr) 2017-04-07
EA026353B1 (ru) 2017-03-31
PT2805940T (pt) 2017-02-03
AU2013210438B2 (en) 2016-11-10
SI2805940T1 (sl) 2017-04-26
MX2014008647A (es) 2014-11-25

Similar Documents

Publication Publication Date Title
CY1118644T1 (el) Ενωση καρβοξαμιδιου πυραζινης
CY1117546T1 (el) Eνωση διαμινο ετεροκυκλικου καρβοξαμιδιου
CY1122243T1 (el) Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt
CY1122886T1 (el) Αναστολεις βρωμοεπικρατειων
CY1122144T1 (el) Αιθερες αρυλιου και χρησεις εξ αυτων
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
AR122785A2 (es) Inhibidores de kras g12c y métodos para su uso
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
CY1121831T1 (el) Παραγωγα θειενο [2,3-c] πυρρολ-4-ονης ως αναστολεις της erk
CY1118933T1 (el) Anti-cxcr1 συνθεσεις και μεθοδοι
CY1115420T1 (el) Δικυκλικες ενωσεις και οι χρησεις τους ως διπλοι αναστολεις c-src/jak
UY33359A (es) Inhibidores de la triosina de bazo (syk) y sus metodos de preparacion
EP3529315A4 (en) COMPOUNDS AND METHODS OF Awareness Raising Cancer Cells To TYROSINE KINASE INHIBITORS
TR201902525T4 (tr) Janus ile alakalı kinazların (jak) inhibitörleri olarak bir veya daha fazla ilave ajan ile pirolo [2,3-d]pirimidin türevlerinin kombinasyonu.
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
EA201491595A1 (ru) Азотсодержащее ароматическое гетероциклическое соединение
EA202191009A1 (ru) Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k
CL2015002932A1 (es) Inhibidores de proteína quinasa
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
CY1114608T1 (el) Θεραπειες συνδυασμου που περιλαμβανουν κινοξαλινη αναστολεα pι3k αλφα για χρηση στην θεραπεια του καρκινου
CY1124391T1 (el) Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t&gt;c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CY1116569T1 (el) Παραγωγα πυριδινυλο- και πυραζινυλο-μεθυλοξυ-αρυλιου χρησιμα ως αναστολεις της τυροσινης κινασης σπληνας (syk)
CY1118371T1 (el) Αναστολεις του iap
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.